GlassScriptPhysician profile
David C Saunders
NPI 1477786457
$1,395.65
in general payments reported to CMS, 2019-2025
22 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $324 · 2022: $200 · 2023: $142 · 2024: $320 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $144.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $93.38 | 2022-2025 | Farxiga, Airsupra |
| Vanda Pharmaceuticals INC. | $83.18 | 2025 | Hetlioz, Fanapt |
| Amarin Pharma, INC. | $76.01 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.05 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $65.76 | 2021-2024 | |
| Glaxosmithkline, LLC. | $58.90 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $52.44 | 2023-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $52.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.83 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $48.78 | 2023-2025 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $43.76 | 2021 | |
| Exact Sciences Corporation | $31.79 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $29.12 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.92 | 2021 | |
| Lundbeck LLC | $19.18 | 2022 | |
| Pfizer INC. | $18.12 | 2023 | |
| Ardelyx, INC. | $17.45 | 2025 | Ibsrela |
| Lilly USA, LLC | $16.30 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $13.25 | 2022 | |
| Eisai INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.